Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Henriques Md"'
Autor:
Maite M.T. van Haeren, MD, Senta Jorinde Raasveld, MD, Mina Karami, MD, PhD, Dinis Dos Reis Miranda, MD, PhD, Loes Mandigers, MD, Dieter F. Dauwe, MD, PhD, Erwin De Troy, MD, Federico Pappalardo, MD, PhD, Evgeny Fominskiy, MD, PhD, Walter M. van den Bergh, MD, PhD, Annemieke Oude Lansink-Hartgring, MD, PhD, Franciska van der Velde, MD, Jacinta J. Maas, MD, PhD, Pablo van de Berg, MD, PhD, Maarten de Haan, ECCP, Dirk W. Donker, MD, PhD, Christiaan L. Meuwese, MD, PhD, Fabio Silvio Taccone, MD, PhD, Lorenzo Peluso, MD, Roberto Lorusso, MD, PhD, Thijs S.R. Delnoij, MD, Erik Scholten, MD, Martijn Overmars, MD, Višnja Ivancan, MD, PhD, Robert Bojčić, MD, Jesse de Metz, MD, PhD, Bas van den Bogaard, MD, PhD, Martin de Bakker, MB, BCh, BAO, Benjamin Reddi, MBChB, PhD, Greet Hermans, MD, PhD, Lars Mikael Broman, MD, PhD, José P.S. Henriques, MD, PhD, Jimmy Schenk, PhD, Alexander P.J. Vlaar, MD, PhD, Marcella C.A. Müller, MD, PhD
Publikováno v:
Critical Care Explorations, Vol 5, Iss 8, p e0949 (2023)
OBJECTIVES:. To achieve optimal hemostatic balance in patients on extracorporeal membrane oxygenation (ECMO), a liberal transfusion practice is currently applied despite clear evidence. We aimed to give an overview of the current use of plasma, fibri
Externí odkaz:
https://doaj.org/article/ce62ab5e9cad4720bde961d6de5802f5
Autor:
Astrid C. van Nieuwkerk, MD, Raquel B. Santos, MD, Samantha Sartori, PhD, Ander Regueiro, MD, Didier Tchétché, MD, Roxana Mehran, MD, Ronak Delewi, MD, PhD, Flavio S. De Brito, Jr., MD, PhD, Flavio Tarasoutchi, MD, Marco Barbanti, MD, Ran Kornowski, MD, Katia Orvin, MD, Azeem Latib, MD, Matteo Pagnesi, MD, Augusto D'Onofrio, MD, PhD, Giuseppe Tarantini, MD, PhD, Flavio Ribichini, MD, PhD, Mattia Lunardi, MD, Jan Baan, MD, PhD, Jan Tijssen, PhD, José P.S. Henriques, MD, PhD, Francisco Ten, Nicolas Dumonteil, MD, Angie Ghattas, MD, Paola D'Errigo, MSc, Juan Manuel Nogales, Thomas Modine, MD, George Dangas, MD, PhD
Publikováno v:
JTCVS Open, Vol 6, Iss , Pp 26-36 (2021)
Objective: This study sought to investigate the effect of body mass index on outcomes in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation. Methods: A total of 12,381 patients undergoing transfemoral transc
Externí odkaz:
https://doaj.org/article/957d1e63d62942b9985ef403790cb049
Publikováno v:
JACC: Case Reports, Vol 2, Iss 12, Pp 1884-1887 (2020)
We describe a novel approach for percutaneous insertion of the Impella 2.5 (Abiomed Inc., Danvers, Massachusetts) through the brachial artery in 2 patients with inaccessible femoral arteries. Placement of the Impella 2.5 via the brachial artery was f
Externí odkaz:
https://doaj.org/article/8e8c1b71e79349d6b0e8d747fe9559fe
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Correa LB; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy & Synthesis of New Radiopharmaceuticals, Rio de Janeiro RJ, 21941906, Brazil.; Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, 21040-360, Brazil., Gomes-da-Silva NC; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy & Synthesis of New Radiopharmaceuticals, Rio de Janeiro RJ, 21941906, Brazil., Dos Santos CC; Biophysics & Nanosystems Laboratory, Federal University of Maranhão, Department of Physics, São Luis, MA, 65065690, Brazil., Rebelo Alencar LM; Biophysics & Nanosystems Laboratory, Federal University of Maranhão, Department of Physics, São Luis, MA, 65065690, Brazil., Graças Muller de Oliveira Henriques MD; Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, 21040-360, Brazil., Bhattarai P; Department of Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy, Texas A&M University, College Station, TX 77843, USA., Zhu L; Department of Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy, Texas A&M University, College Station, TX 77843, USA., Noronha Souza PF; Drug Research & Development Center, Department of Physiology & Pharmacology, Federal University of Ceará, Ceará, 60430275, Brazil., Rosas EC; Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, 21040-360, Brazil.; Master & Doctoral Degree in Drugs Translational Research, Farmanguinhos - Oswaldo Cruz Foundation, Rio de Janeiro, 21040-360, Brazil., Santos-Oliveira R; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy & Synthesis of New Radiopharmaceuticals, Rio de Janeiro RJ, 21941906, Brazil.; Rio de Janeiro State University, Laboratory of Radiopharmacy & Nanoradiopharmaceuticals, Rio de Janeiro, RJ, 23070200, Brazil.
Publikováno v:
Therapeutic delivery [Ther Deliv] 2024 Mar 12. Date of Electronic Publication: 2024 Mar 12.
Autor:
Gier C; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA., Kalogeropoulos A; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA., Henriques MD; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA., Al-Sadawi M; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA., Aslam F; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA., Tao M; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA., Almasry IO; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA., Singh A; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA., Rashba EJ; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA., Fan R; Stony Brook Heart Institute Stony Brook University Hospital Stony Brook NY USA.
Publikováno v:
Journal of the American Heart Association [J Am Heart Assoc] 2024 Jan 16; Vol. 13 (2), pp. e029788. Date of Electronic Publication: 2024 Jan 12.
Publikováno v:
JACC. Advances [JACC Adv] 2023 Aug 22; Vol. 2 (7), pp. 100561. Date of Electronic Publication: 2023 Aug 22 (Print Publication: 2023).
Autor:
Borges PV; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Moret KH; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Maya-Monteiro CM; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Souza-Silva F; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Alves CR; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Batista PR; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Caffarena ER; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Pacheco P; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Henriques Md; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Penido C; Laboratory of Applied Pharmacology, Institute of Drug Technology (P.V.B., K.H.M., P.P., M.d.G.H., C.P.), Computational Science Program, Computational Biophysics and Molecular Modeling Group (P.R.B.; E.R.C.), and Center for Technological Development in Health (M.G.H., C.P.), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; and Laborator of Immunopharmacology (C.M.M.-M.) and Molecular Biology and Endemic Diseases (F.S.S., C.R.A.), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil cpenido@cdts.fiocruz.br.
Publikováno v:
Molecular pharmacology [Mol Pharmacol] 2015 Nov; Vol. 88 (5), pp. 949-61. Date of Electronic Publication: 2015 Sep 01.
Autor:
Costa MF; Laboratório de Farmacologia Aplicada, Departamento de Farmacologia, Farmanguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil. mfcosta@cdts.fiocruz.br.; Centro de Desenvolvimento Tecnológico em Saúde, Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças Negligenciadas (INCT-IDN), Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. mfcosta@cdts.fiocruz.br., de Negreiros CB; Laboratório de Farmacologia Aplicada, Departamento de Farmacologia, Farmanguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil. catarinanegreiros@far.fiocruz.br., Bornstein VU; Laboratório de Farmacologia Aplicada, Departamento de Farmacologia, Farmanguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil. victo.bornstein@mssm.edu.; Mount Sinai School of Medicine, New York City, USA. victo.bornstein@mssm.edu., Valente RH; Laboratório de Toxinologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. rhv4u@ioc.fiocruz.br., Mengel J; Laboratório de Imunologia, Faculdade de Medicina de Petrópolis, Petrópolis, Rio de Janeiro, Brazil. jomengel@fiocruz.br.; Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. jomengel@fiocruz.br., Henriques Md; Laboratório de Farmacologia Aplicada, Departamento de Farmacologia, Farmanguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil. gracahenriques@fiocruz.br.; Centro de Desenvolvimento Tecnológico em Saúde, Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças Negligenciadas (INCT-IDN), Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. gracahenriques@fiocruz.br., Benjamim CF; Laboratório de Inflamação, Estresse Oxidativo e Câncer, Centro de Ciências da Saúde, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. cbenjamim@icb.ufrj.br., Penido C; Laboratório de Farmacologia Aplicada, Departamento de Farmacologia, Farmanguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil. cpenido@cdts.fiocruz.br.; Centro de Desenvolvimento Tecnológico em Saúde, Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças Negligenciadas (INCT-IDN), Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. cpenido@cdts.fiocruz.br.
Publikováno v:
BMC immunology [BMC Immunol] 2015 Jun 03; Vol. 16, pp. 36. Date of Electronic Publication: 2015 Jun 03.
Autor:
Souza MC; Centro de Desenvolvimento Tecnológico em Saúde, Centro de Desenvolvimento Tecnológico em Saúde-Fiocruz, Rio de Janeiro, RJ, Brasil., Padua TA; Centro de Desenvolvimento Tecnológico em Saúde, Centro de Desenvolvimento Tecnológico em Saúde-Fiocruz, Rio de Janeiro, RJ, Brasil., Torres ND; Centro de Desenvolvimento Tecnológico em Saúde, Centro de Desenvolvimento Tecnológico em Saúde-Fiocruz, Rio de Janeiro, RJ, Brasil., Costa MF; Centro de Desenvolvimento Tecnológico em Saúde, Centro de Desenvolvimento Tecnológico em Saúde-Fiocruz, Rio de Janeiro, RJ, Brasil., Facchinetti V; Centro de Desenvolvimento Tecnológico em Saúde, Centro de Desenvolvimento Tecnológico em Saúde-Fiocruz, Rio de Janeiro, RJ, Brasil., Gomes CR; Centro de Desenvolvimento Tecnológico em Saúde, Centro de Desenvolvimento Tecnológico em Saúde-Fiocruz, Rio de Janeiro, RJ, Brasil., Souza MV; Centro de Desenvolvimento Tecnológico em Saúde, Centro de Desenvolvimento Tecnológico em Saúde-Fiocruz, Rio de Janeiro, RJ, Brasil., Henriques Md; Centro de Desenvolvimento Tecnológico em Saúde, Centro de Desenvolvimento Tecnológico em Saúde-Fiocruz, Rio de Janeiro, RJ, Brasil.
Publikováno v:
Memorias do Instituto Oswaldo Cruz [Mem Inst Oswaldo Cruz] 2015 Jun; Vol. 110 (4), pp. 560-5. Date of Electronic Publication: 2015 May 26.